Elite Pharmaceuticals ( (ELTP) ) has issued an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Elite Pharmaceuticals announced the launch of its generic version of Vyvanse® (Lisdexamfetamine Disylate) in various strengths, targeting the ADHD treatment market. The product, which is marketed under the Elite Laboratories, Inc. label, is expected to capture a portion of the $4.3 billion annual sales reported by IQVIA for the original product, potentially enhancing Elite’s market presence in the generic pharmaceutical industry.
More about Elite Pharmaceuticals
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, and distributes niche generic products. Their product lines include immediate-release and controlled-release solid oral dose products, marketed under the Elite Laboratories label and through third-party licenses. The company operates a cGMP and DEA registered facility for research, development, and manufacturing in Northvale, NJ.
YTD Price Performance: 282.14%
Average Trading Volume: 2,874,817
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $571.6M
Learn more about ELTP stock on TipRanks’ Stock Analysis page.
